Visual reading for [18F]Florzolotau Tau PET scans in progressive supranuclear palsy
Authors:
- 1 October 2024
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (2) , 586-598
Abstract
Purpose The identification of tau accumulation within living brains holds significant potential in facilitating accurate diagnosis of progressive supranuclear palsy (PSP). While visual assessment is frequently employed, standardized methods for tau positron emission tomography (PET) specifically in PSP are absent. We aimed to develop a visual reading algorithm dedicated to the evaluation of [18F]Florzolotau PET in PSP. Methods 148 PSP and 30 healthy volunteers were divided into a development set (for the establishment of the reading rules; n = 89) and a testing set (for the validation of the reading rules; n = 89). For differential diagnosis, 55 α-synucleinopathies were additionally included into the testing set. The visual reading method was established by an experienced assessor (Reader 0) and was then validated by Reader 0 and two additional readers on regional and overall binary manners. A positive binding in both midbrain and globus pallidus/putamen regions was characterized as a PSP-like pattern, whereas any other pattern was classified as non-PSP-like. Results Reader 1 (94.4%) and Reader 2 (93.8%) showed excellent agreement for the overall binary determination against Reader 0. The regional binary determinations of midbrain and globus pallidus/putamen showed excellent agreement among readers (kappa > 0.80). The overall binary evaluation demonstrated reproducibility of 86.1%, 94.4% and 77.8% for three readers. The visual reading algorithm showed high agreement with regional standardized uptake value ratios and clinical diagnoses. Conclusion Through the application of the suggested visual reading algorithm, [18F]Florzorotau PET imaging demonstrated a robust performance for the imaging diagnosis of PSP.Keywords
Funding Information
- National Natural Science Foundation of China (82272039, 82021002, 82394430, 81971641, 82371266, 82171252, 82171421, 91949118, 82394434)
- Science and Technology Innovation 2030 Major Project (2022ZD0211600)
- National Key R&D Program of China (2022YFC2009902, 2022YFC2009900)
- Shanghai Municipal Science and Technology Major Project (2018SHZDZX01, 21S31902200)
- National Health Commission of PRC (Pro20211231084249000238)
- Research Project of the Shanghai Health Commission (2020YJZX0111)
- Medical Innovation Research Project of the Shanghai Science and Technology Commission (21Y11903300)
- Deutsche Forschungsgemeinschaft (DFG) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy – ID 390857198)
This publication has 23 references indexed in Scilit:
- Clinical Utility of 18F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear PalsyMovement Disorders, 2021
- Cortical [18F]PI‐2620 Binding Differentiates Corticobasal Syndrome SubtypesMovement Disorders, 2021
- Toward a Universal Readout for18F-Labeled Amyloid Tracers: The CAPTAINs StudyJournal of Nuclear Medicine, 2021
- High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer’s and Non-Alzheimer’s Disease TauopathiesNeuron, 2021
- Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear PalsyJAMA Neurology, 2020
- Associations of [18F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose MetabolismFrontiers in Neuroscience, 2020
- Distribution patterns of tau pathology in progressive supranuclear palsyActa Neuropathologica, 2020
- Automated anatomical labelling atlas 3NeuroImage, 2020
- Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approachesThe Lancet Neurology, 2017
- Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteriaMovement Disorders, 2017